Related Experiment Video
Updated: Jul 3, 2026
08:41
Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Developing anticancer chemotherapy services in a developing country: Hodgkin lymphoma experience
Jagdish Chandra1, Rahul Naithani, Varinder Singh
1Division of Pediatric Hemato-Oncology, Department of Pediatrics, Lady Hardinge Medical College & Kalawati Saran Children's Hospital, New Delhi, India. jchandra55@yahoo.co.in
Pediatric Blood & Cancer
|July 19, 2008
Summary
Developing cancer treatment facilities in India improved outcomes for pediatric Hodgkin lymphoma (HL) patients. The new center effectively managed advanced HL cases, with 80% of patients achieving disease-free survival.
Area of Science:
- Pediatric Oncology
- Hematology
- Cancer Treatment Infrastructure
Background:
- Establishment of new cancer treatment facilities at a medical college hospital in India.
- Focus on developing infrastructure for pediatric cancer care.
Purpose of the Study:
- To report on the development of cancer treatment facilities for pediatric Hodgkin lymphoma (HL).
- To analyze the profile and treatment outcomes of pediatric HL patients at a new center.
Main Methods:
- Evaluation of pediatric HL patients (under 18) using imaging (ultrasonography, CT scans) and bone marrow examination.
- Treatment primarily involved combination chemotherapy (COPP/ABVD), with radiotherapy available nearby.
- Involvement of Radiodiagnosis and Pathology departments for comprehensive patient assessment.
Main Results:
- 35 pediatric HL patients diagnosed; 83% presented with advanced disease (Stage IIb+).
- Mixed cellularity was the most common histological subtype (50.5%).
- 80% of patients achieved disease-free survival after a median follow-up of 4.5 years; chemotherapy was well-tolerated.
Conclusions:
- Pediatric Hodgkin lymphoma in India is often diagnosed at advanced stages.
- Mixed cellularity is the predominant histological subtype in this population.
- An effective pediatric HL treatment program was successfully established.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...